Rheumatology International

, Volume 28, Issue 3, pp 245–251

Etanercept reduces the oxidative stress marker levels in patients with rheumatoid arthritis

Authors

    • Department of Orthopaedic SurgeryHamamatsu University School of Medicine
  • Masaaki Takahashi
    • Department of Orthopaedic SurgeryHamamatsu University School of Medicine
  • Tetsuyuki Nagafusa
    • Department of Orthopaedic SurgeryHamamatsu University School of Medicine
  • Eiji Torikai
    • Department of Orthopaedic SurgeryHamamatsu University School of Medicine
  • Akira Nagano
    • Department of Orthopaedic SurgeryHamamatsu University School of Medicine
Original Article

DOI: 10.1007/s00296-007-0419-1

Cite this article as:
Kageyama, Y., Takahashi, M., Nagafusa, T. et al. Rheumatol Int (2008) 28: 245. doi:10.1007/s00296-007-0419-1

Abstract

This study was performed to evaluate the effects of the TNF-α inhibitor etanercept on oxidation stress markers representing DNA damage, lipid peroxidation, and protein glycosylation. Twenty-two rheumatoid arthritis (RA) patients underwent etanercept treatment. The levels of serum total, urinary total, and urinary free pentosidine, which is an advanced glycation end-product (AGE), of urinary Nε-hexanoyl lysine (Nε-HEL), and of 8-hydroxy-deoxy guanosine (8-OHdG) were measured at baseline and at 3 and 6 months after the initial treatment with etanercept. Serum total and urinary total pentosidine levels were reduced at 6 months after the initial treatment with etanercept, and urinary free pentosidine levels were reduced at 3 and 6 months. Urinary Nε-HEL levels were also reduced at 3 and 6 months, and urinary 8-OHdG levels were reduced at 6 months. Serum total and urinary total pentosidine levels in RA patients correlated with the number of swelling joints and tender joints, and urinary total pentosidine levels correlated with the Disease Activity Score using 28 joints (DAS28). This study demonstrated that etanercept acts as a regulator against pentosidine formation, oxidative DNA damage, and lipid peroxidation in RA patients.

Keywords

EtanerceptRheumatoid arthritisPentosidine8-OHdGOxidative stress

Copyright information

© Springer-Verlag 2007